Eagle Pharmaceuticals Long Term Debt

The latest long-term debt for EGRX is $62M as of June 2023. That compares with $28M in the prior-year period — up 120.9% year over year. Investors often review this figure alongside Eagle Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, EGRX's long-term debt moved from $28M to $62M — a 120.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Eagle Pharmaceuticals's operating scale or balance-sheet position.

A long-term debt figure of $62M for EGRX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting EGRX's long-term debt ($62M), review year-over-year change from $28M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Eagle Pharmaceuticals's long-term debt against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.